comparemela.com

Latest Breaking News On - Vojislav vukovic - Page 1 : comparemela.com

Delcath Systems, Inc (NASDAQ:DCTH) Q4 2023 Earnings Call Transcript

Operator: Good day, and welcome to the Delcath Systems Reports Fourth Quarter and Fiscal Year 2023 Financial Results Conference Call. All participants are in a listen-only mode.

United statesSandra pennellDavid hoffmanGerard michelKevin muirMarie thibaultVojislav vukovicCanaccord genuityUniversity hospital south hamptonSecurities exchangeUniversity hospitalDuke universityOhio state university wexner medical centerValue committeeMelanoma researchMoffitt cancer center

Blue Apron Holdings (NASDAQ: APRN) Charts Path to Profitability in Q2 2023: Debt Elimination and Strategic Transaction

A significant turnaround materialized for Blue Apron (NYSE: APRN), sparking unseen investor support: a brief overview on developments.

Gerard michelVojislav vukovicAccess programNational comprehensive cancer networkDelcath systems incDelcath systemsRight nowExpanded access programRisk evaluationMitigation strategyChief medical officerPrivate investmentPublic equityHepatic delivery systemPercutaneous hepatic perfusionUveal melanoma

Delcath Systems (NASDAQ: DCTH) HEPZATO KIT Achieves FDA Approval: A Pivotal Step in Liver Cancer Treatment

A deconstructed view on Delcath Systems' (NASDAQ: DCTH) latest FDA approval and key points that are important for investors to understand.

Vojislav vukovicGerard michelAccess programDelcath systems incNational comprehensive cancer networkDelcath systemsRight nowExpanded access programRisk evaluationMitigation strategyChief medical officerPrivate investmentPublic equityHepatic delivery systemPercutaneous hepatic perfusionUveal melanoma

FDA Approves Hepzato Kit for Liver-Directed Treatment of Metastatic Uveal Melanoma

Melphalan/hepatic delivery system (Hepzato Kit; Delcath Systems Inc) is currently the only liver-directed therapy approved by the FDA for the treatment of netastatic uveal melanoma and percutaneous hepatic perfusion.

Yurii kibalnikVojislav vukovicGerard michelNational comprehensive cancer networkAccess programDelcath systems incHepzato kitDelcath systemsCurrent opinionComprehensive cancer networkDisease control rateRisk evaluation mitigation strategyExpanded access program

Delcath Systems, Inc Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

/PRNewswire/ Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the.

Vojislav vukovicGerard michelBen shamsianExchange commissionPrnewswire delcath systems incDelcath systems incDrug administrationNational comprehensive cancer networkAccess programInternational tollBusiness update callHepatic delivery systemComprehensive cancer networkChief executiveExpanded access programDisease control rate

vimarsana © 2020. All Rights Reserved.